Pediatric Hematologist-Oncologist: Natalie Kamberos, DO | Loyola Medicine

COVID-19 (Coronavirus) Update

Loyola Medicine is resuming select health care services. Learn more about resumption of services.

Natalie Kamberos, DO, FAAP


Pediatric Hematology/Oncology
Assistant Professor

Languages Spoken

English, Spanish (intermediate)

Clinical Expertise

  • Anemia
  • Bleeding Disorders In Children And Adolescents
  • Blood Diseases (Benign)
  • Leukemia
  • Lymphoma
  • Sickle Cell Disease

About Dr. Kamberos

Medical Missions and Outreach Work, Baking, Cubs baseball, Singing, Dogs

Medical Education

Medical School
Kansas City University of Medicine and Biosciences
Blank Children's Hospital - Pediatrics
  • University of Iowa Hospitals and Clinics - Pediatrics

Board Certification

American Board of Pediatrics
Pediatric Hematology Oncology, American Board of Pediatrics Subspecialty, Pediatric Hematology & Oncology


  • CDKN1A and FANCD2 are potential oncotargets in Burkitt lymphoma and multiple myeloma. Han, SS; Tompkins, VS; Son, DJ; Han, S; Yun, H; Kamberos, NL; Dehoedt, CL; Gu, C; Holman, C; Tricot, G; Zhan, F; Janz, S, Experimental hematology & oncology
  • A new model of LMP1-MYC interaction in B cell lymphoma. Ontiveros, EP; Halwani, A; Stunz, LL; Kamberos, N; Olivier, AK; Janz, S; Bishop, GA, Leukemia & lymphoma
  • Choroidal schwannoma in a 6-month-old girl. Chen, JJ; Kamberos, NL; O'Dorisio, MS; Syed, NA; Boldt, C, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus
View All ResearchShow Less
  • Piperlongumine inhibits the proliferation and survival of B-cell acute lymphoblastic leukemia cell lines irrespective of glucocorticoid resistance. Han, SS; Han, S; Kamberos, NL, Biochemical and biophysical research communications